According to Nova one advisor, the global Genome Editing market size is expected to hit around USD 25.4 billion by 2030 from valued at USD 4.7 billion in 2021 and growing at a CAGR of 28.4% from 2022 to 2030.
Key Takeaways:
Report Scope of the Genome Editing Market
Report Coverage |
Details |
Market Size |
USD 25.4 Billion by 2030 |
Growth Rate |
CAGR of 28.4% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Technology, delivery method, application, mode, end-use and Region, |
Companies Mentioned |
Merck KGaA; Cibus; Recombinetics, Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics, Inc.; Caribou Biosciences, Inc.; Cellectis; AstraZeneca; Takara Bio USA; Horizon Discovery Group plc; Integrated DNA Technologies, Inc.; Egenesis Inc.; GenScript; New England Biolabs; OriGene Technologies, Inc.; Lonza; Thermo Fisher Scientific, Inc. |
Increasing implementation of CRISPR genome editing technology coupled with rising synthetic gene demand in diverse biotechnology domains has primarily driven the market growth over the past few years.
Furthermore, the development of CRISPR -based novel diagnostic tools to mitigate the adverse impact of the COVID-19 pandemic is driving the market. For instance, in March 2021, a team of researchers from the Nanyang Technological University developed a diagnostic test - VaNGuard (Variant Nucleotide Guard) based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, thereby increasing the adoption of CRISPR genome editing technology in the diagnostics arena.
Apart from this, continuous technological advancements in gene-editing tools are a major contributing factor for revenue generation in this market. For instance, in April 2021, researchers from Wyss Institute for Biologically Inspired Engineering at Harvard developed Retron Library Recombineering (RLR) - a new gene-editing tool that enabled the performance of millions of genetic experiments simultaneously, thereby providing better editing rates.
Moreover, the market is witnessing intensified competition among the market players owing to the expanding applications of genome editing tools. There has been an increased focus on the highly adaptable CRISPR technology. For instance, in April 2021, Vertex Pharmaceuticals paid USD 900 million to CRISPR Therapeutics to develop, manufacture and commercialize CRISPR-Cas9 gene-edited therapy for beta-thalassemia and sickle-cell disease. Such initiatives are anticipated to propel market growth.
The expanding gene therapy marketspace has shown significant interest in gene manipulation technologies, thus augmenting the revenue growth. In April 2021, a genome editing consortium announced its plan to develop a new genome editing 'toolkit'. This is aimed to boost gene therapy development. The amount of USD 190 million was granted to the Somatic Cell Genome Editing Consortium for the development of genome editing methods and approaches.
Delivery Method Insights
The ex-vivo delivery method segment dominated the market and accounted for the largest revenue share of 58.2% in 2021. This can be attributed to the advantages offered by this mode type such as ease of control in DNA modification. The growing clinical trial pipeline that deploys genome editing tools has spurred the ex-vivo delivery segment growth with the increased usage of this delivery method.
On the other hand, the in-vivo gene delivery method accounted for lower revenue generation because of challenges that occurred during the process such as off-target effects. However, focused efforts are being taken to overcome the challenges with growing clinical trials focused on easy target tissues using in-vivo delivery.
Application Insights
The developments in gene editing systems have revolutionized the genetic engineering space, with cell line engineering at the forefront, accounting for the largest revenue share of 59.8% in 2021. This can be attributed to the rapidly growing field of gene and stem cell therapy. The usage of CRISPR gene editing in human-induced pluripotent stem cells (hiPSCs) related programs has important implications in stem cell research for the treatment of various diseases. The clinical application segment dominated the market and accounted for the significant revenue share in 2020.
Furthermore, the CRISPR technology is widely being applied to enhance the productivity of CHO cell lines. These cell lines are prominently used in the production of large molecule therapeutics. Thus, with the application of the CRISPR tool, the biopharmaceutical marketspace is witnessing advancements consequently driving the market for genome editing.
Besides, genetic engineering, genome editing technologies have high potential growth in clinical applications such as diagnostics and therapy development. For instance, an ongoing clinical trial sponsored by Cellectis S.A. is aimed to evaluate the efficacy and safety of UCART123 in patients with R/R Acute Myeloid Leukemia. This therapy is based on TALEN gene-editing technology.
End-use Insights
The biotechnology and pharmaceutical companies segment dominated the market and accounted for the largest revenue share of 50.4% in 2021. The presence of a growing number of research activities for novel therapeutic development is the major factor contributing to the segment revenue generation. Moreover, global pharmaceutical companies are collaborating with emerging companies to develop novel technologies.
For instance, in April 2021, CANbridge Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc signed a strategic collaboration and licensing agreement to address rare and serious diseases. Through this agreement, CANbridge Pharmaceuticals, Inc. gained rights to the latter company’s gene-editing platforms. Similarly, in October 2020, Scribe Therapeutics collaborated with Biogen for the development of CRISPR-based genetic medicines for neurological diseases such as Amyotrophic Lateral Sclerosis.
On the other hand, government research and academic institutes are anticipated to witness healthy growth in the near future owing to the increasing uptake of gene-editing technologies in university-level projects. Active engagement of research institutes further supplements the segment growth. For instance, research institutes such as Baylor College of Medicine, Rice University, and Whitehead Institute are actively involved in efforts to advance genome editing.
Mode Insights
The contract-based genome editing segment dominated the market and accounted for the largest revenue share of 52.9% in 2021. The high cost of associated infrastructure coupled with increasing collaborations between market entities has resulted in a significant market share of contract services in the global market. For instance, in September 2020, ERS Genomics and Applied StemCell, Inc. signed an agreement for the commercialization of genome editing services.
Similarly, in November 2020, Eli Lilly and the company collaborated with Precision BioSciences, Inc. to use the latter company’s proprietary ARCUS genome editing platform to develop potential in-vivo therapeutics for genetic disorders. Such collaborations have intensified the market competition leading to organic revenue growth.
Well-established companies such as Merck KGaA and Thermo Fisher Scientific are involved in providing custom vectors for cell line editing and engineering. Such services are anticipated to witness growth in the coming years, thereby fueling revenue growth. The rapidly growing demand from gene therapy market players would also propel the revenue generation for contract manufacturers.
Regional Insights
North America dominated the genome editing market and accounted for the largest revenue share of 39.4% in 2021. The presence of strong research, as well as a commercial base for advanced therapy development coupled with a high number of clinical trials being conducted for gene and stem cell therapies in the region, has majorly contributed to the dominance of the market in the region.
Furthermore, the increasing number of patents awarded to U.S.-based key players has also accelerated the uptake of these tools in the country leading to significant market growth. For instance, Merck KGaA recently announced that two patents of the company have been approved in the U.S. for CRISPR gene-editing technologies.
On the other hand, in Asia Pacific, the market is anticipated to witness the fastest growth rate throughout the forecast period. In November 2021, China announced its ten most significant advances in the agriculture sector, out of which one was gene-editing technology, thus representing the high market penetration of this space in the country.
Some of the prominent players in the Genome Editing Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Genome Editing market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1 Information Procurement
1.2 Data Analysis
1.3 Market segmentation & scope
1.4 Market definition
1.5 Information procurement
1.5.1 Purchased database
1.5.2 nova one advisor’s internal database
1.5.3 Secondary sources & Third-Party perspectives
1.5.4 Primary research
1.6 Information analysis
1.6.1 Data analysis models
1.7 Market formulation & data visualization
1.8 Data validation & publishing
Chapter 2 Genome Editing Market: Executive Summary
2.1 Genome Editing Market Outlook, 2017 - 2030
2.2 Segment Outlook
Chapter 3 Genome Editing Market: Industry Outlook
3.1 Market Pyramid Analysis
3.1.1 Parent Market
3.1.2 Ancillary Market
3.2 Market Dynamics Analysis
3.2.1 Market Driver Analysis
3.2.1.1 Success in pre-clinical models drives demands for genome editing therapeutics
3.2.1.2 Rising competition amongst market participants for business development
3.2.1.3 Easy editing solutions for the development of therapeutics for a broad range of diseases
3.2.1.4 Increasing demand for synthetic genes and genetically modified organisms
3.2.1.5 Technological advancements in gene editing technologies
3.2.1.6 Rising adoption in agricultural biotechnology
3.2.2 Market Restraint Analysis
3.2.2.1 Challenges with respect to clinical translation
3.2.2.2 Regulatory, scientific, and ethical challenges pertaining to the use of genetically modified products
3.2.2.3 Off-target effects of CRISPR technology
3.3 Penetration &Growth Prospect MappingforTechnology, 2020
3.4 Genome editing -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis - Porter’s
3.6 Genome Editing Technologies: Pipeline Analysis
3.6.1 Sangamo
3.6.2 Cellectis
3.6.3 Calyxt
3.6.4 bluebird bio
3.6.5 Editas Medicine
3.6.6 Intellia Therapeutics, Inc.
3.6.7 CRISPR Therapeutics
3.6.8 Precision Biosciences
3.6.9 Precision Biosciences (Non-medical domain)
3.6.10 Caribou Biosciences
3.6.11 Cibus
3.6.12 Recombinetics, Inc
3.7 Intellectual Property
3.8 Regulatory Issues
3.8.1 Orphan diseases
3.8.2 Germline editing
3.8.3 Safety issues
3.9 COVID-19 Impact Analysis
Chapter 4 Genome Editing Market: Technology Business Analysis
4.1 Genome Editing Market: Technology Movement Analysis
4.2 Genome EditingTechnology Comparison
4.3 (CRISPR)/Cas9
4.3.1 Global (CRISPR)/Cas9 market, 2017 - 2030
4.4 TALENs/MegaTALs
4.4.1 Global TALENs/MegaTALs market, 2017 - 2030
4.5 ZFN
4.5.1 Global ZFN market, 2017 - 2030
4.6 Meganucleases
4.6.1 Global Meganucleases market, 2017 - 2030
4.7 Other Technologies
4.7.1 Global other technologies market, 2017 - 2030
Chapter 5 Genome Editing Market: Delivery Method Business Analysis
5.1 Genome Editing Market: Delivery Method Movement Analysis
5.1.1 Comparison of Delivery Methods
5.1.1.1 Viral delivery
5.1.1.1.1 AAV (Adeno Associated Virus)
5.1.1.1.2 IDLV (Integrase Deficient Lentivirus).
5.1.1.2 Non-viral delivery
5.1.1.2.1 Lipid Mediated
5.1.1.2.2 Electroporation
5.2 Ex-vivo
5.2.1 Global ex-vivo delivery market, 2017 - 2030
5.3 In-vivo
5.3.1 Global in-vivo delivery market, 2017 - 2030
Chapter 6 Genome Editing Market: Application Business Analysis
6.1 Market: ApplicationMovement Analysis
6.2 Genetic Engineering
6.2.1 Market, 2017 - 2030
6.2.1.1 Cell line engineering
6.2.1.1.1 Market, 2017 - 2030
6.2.1.2 Animal genetic engineering
6.2.1.2.1 Market, 2017 - 2030
6.2.1.3 Plant genetic engineering
6.2.1.3.1 Market, 2017 - 2030
6.2.1.4 Others
6.2.1.4.1 Global others market, 2017 - 2030
6.3 Clinical Applications
6.3.1 Market for clinical applications, 2017 - 2030
6.3.1.1 Diagnostics
6.3.1.1.1 Market for diagnostics applications, 2017 - 2030
6.3.1.2 Therapy Development
6.3.1.2.1 Market for therapy development applications, 2017 - 2030
Chapter 7 Genome Editing Market: End-Use Business Analysis
7.1 Market: End-use Movement Analysis
7.2 Biotechnology & Pharmaceutical Companies
7.2.1 Market, 2017 - 2030
7.3 Academic & Government Research Institutes
7.3.1 Market, 2017 - 2030
7.4 Contract Research Organizations (CROs)
7.4.1 Market, 2017 - 2030
Chapter 8 Genome Editing Market: Mode Business Analysis
8.1 Market: Mode Movement Analysis
8.2 In-house
8.2.1 Market, 2017 - 2030
8.3 Contract
8.3.1 Market, 2017 - 2030
Chapter 9 Genome Editing Market: Regional Business Analysis
9.1 Market Share By Region, 2020 & 2030
9.2 North America
9.2.1 Market, 2017 - 2030
9.2.2 U.S.
9.2.2.1 U.S. genome editing market, by technology, 2017 - 2030
9.2.2.2 U.S. genome editing market, by delivery method, 2017 - 2030
9.2.2.3 U.S. genome editing market, by application, 2017 - 2030
9.2.2.4 U.S. genome editing market, by end-use, 2017 - 2030
9.2.2.5 U.S. genome editing market, by mode, 2017 - 2030
9.2.3 Canada
9.2.3.1 Canada genome editing market, by technology, 2017 - 2030
9.2.3.2 Canada genome editing market, by delivery method, 2017 - 2030
9.2.3.3 Canada genome editing market, by application, 2017 - 2030
9.2.3.4 Canada genome editing market, by end-use, 2017 - 2030
9.2.3.5 Canada genome editing market, by mode, 2017 - 2030
9.3 Europe
9.3.1 Europe genome editing market, 2017 - 2030
9.3.2 Germany
9.3.2.1 Germany genome editing market, by technology, 2017 - 2030
9.3.3.2 Germany genome editing market, by delivery method, 2017 - 2030
9.3.3.3 Germany genome editing market, by application, 2017 - 2030
9.3.3.4 Germany genome editing market, by end-use, 2017 - 2030
9.3.3.5 Germany genome editing market, by mode, 2017 - 2030
9.3.3 U.K.
9.3.3.1 U.K. genome editing market, by technology, 2017 - 2030
9.3.3.2 U.K. genome editing market, by delivery method, 2017 - 2030
9.3.3.3 U.K. genome editing market, by application, 2017 - 2030
9.3.3.4 U.K. genome editing market, by end-use, 2017 - 2030
9.3.3.5 U.K. genome editing market, by mode, 2017 - 2030
9.3.4 Italy
9.3.4.1 Italy genome editing market, by technology, 2017 - 2030
9.3.4.2 Italy genome editing market, by delivery method, 2017 - 2030
9.3.4.3 Italy genome editing market, by application, 2017 - 2030
9.3.4.4 Italy genome editing market, by end-use, 2017 - 2030
9.3.4.5 Italy genome editing market, by mode, 2017 - 2030
9.3.5 France
9.3.5.1 France genome editing market, by technology, 2017 - 2030
9.3.5.2 France genome editing market, by delivery method, 2017 - 2030
9.3.5.3 France genome editing market, by application, 2017 - 2030
9.3.5.4 France genome editing market, by end-use, 2017 - 2030
9.3.5.5 France genome editing market, by mode, 2017 - 2030
9.3.6 Spain
9.3.6.1 Spain genome editing market, by technology, 2017 - 2030
9.3.6.2 Spain genome editing market, by delivery method, 2017 - 2030
9.3.6.3 Spain genome editing market, by application, 2017 - 2030
9.3.6.4 Spain genome editing market, by end-use, 2017 - 2030
9.3.6.5 Spain genome editing market, by mode, 2017 - 2030
9.4 Asia Pacific
9.4.1 Asia Pacific genome editing market, 2017 - 2030
9.4.2 Japan
9.4.2.1 Japan genome editing market, by technology, 2017 - 2030
9.4.2.2 Japan genome editing market, by delivery method, 2017 - 2030
9.4.2.3 Japan genome editing market, by application, 2017 - 2030
9.4.2.4 Japan genome editing market, by end-use, 2017 - 2030
9.4.2.5 Japan genome editing market, by mode, 2017 - 2030
9.4.3 China
9.4.3.1 China genome editing market, by technology, 2017 - 2030
9.4.3.2 China genome editing market, by delivery method, 2017 - 2030
9.4.3.3 China genome editing market, by application, 2017 - 2030
9.4.3.4 China genome editing market, by end-use, 2017 - 2030
9.4.3.5 China genome editing market, by mode, 2017 - 2030
9.4.4 South Korea
9.4.4.1 South Korea genome editing market, by technology, 2017 - 2030
9.4.4.2 South Korea genome editing market, by delivery method, 2017 - 2030
9.4.4.3 South Korea genome editing market, by application, 2017 - 2030
9.4.4.4 South Korea genome editing market, by end-use, 2017 - 2030
9.4.4.5 South Korea genome editing market, by mode, 2017 - 2030
9.4.5 India
9.4.5.1 India genome editing market, by technology, 2017 - 2030
9.4.5.2 India genome editing market, by delivery method, 2017 - 2030
9.4.5.3 India genome editing market, by application, 2017 - 2030
9.4.5.4 India genome editing market, by end-use, 2017 - 2030
9.4.5.5 India genome editing market, by mode, 2017 - 2030
9.5 Latin America
9.5.1 Latin America genome editing market, 2017 - 2030
9.5.2 Brazil
9.5.2.1 Brazil genome editing market, by technology, 2017 - 2030
9.5.2.2 Brazil genome editing market, by delivery method, 2017 - 2030
9.5.2.3 Brazil genome editing market, by application, 2017 - 2030
9.5.2.4 Brazil genome editing market, by end-use, 2017 - 2030
9.5.2.5 Brazil genome editing market, by mode, 2017 - 2030
9.5.3 Mexico
9.5.3.1 Mexico genome editing market, by technology, 2017 - 2030
9.5.3.2 Mexico genome editing market, by delivery method, 2017 - 2030
9.5.3.3 Mexico genome editing market, by application, 2017 - 2030
9.5.3.4 Mexico genome editing market, by end-use, 2017 - 2030
9.5.3.5 Mexico genome editing market, by mode, 2017 - 2030
9.6 Middle East & Africa
9.6.1 Middle East & Africa genome editing market, 2017 - 2030
9.6.2 South Africa
9.6.2.1 South Africa genome editing market, by technology, 2017 - 2030
9.6.2.2 South Africa genome editing market, by delivery method, 2017 - 2030
9.6.2.3 South Africa genome editing market, by application, 2017 - 2030
9.6.2.4 South Africa genome editing market, by end-use, 2017 - 2030
9.6.2.5 South Africa genome editing market, by mode, 2017 - 2030
9.6.3 Saudi Arabia
9.6.3.1 Saudi Arabia genome editing market, by technology, 2017 - 2030
9.6.3.2 Saudi Arabia genome editing market, by delivery method, 2017 - 2030
9.6.3.3 Saudi Arabia genome editing market, by application, 2017 - 2030
9.6.3.4 Saudi Arabia genome editing market, by end-use, 2017 - 2030
9.6.3.5 Saudi Arabia genome editing market, by mode, 2017 - 2030
Chapter 10 Genome Editing Market: Competitive Landscape
10.1 Strategy Framework
10.2 Market Participation Categorization
10.3 Strategic Alliance Analysis
10.3.1 Mergers & Acquisitions
10.3.2 Technological Collaborations
10.3.3 Licensing and partnership
10.4 Recent Developments & Impact Analysis
10.5 List of Potential End-users
10.6 Company Profiles
10.6.1 Merck KGaA
10.6.1.1 Company overview
10.6.1.1.1 Sigma-Aldrich Co. LLC
10.6.1.2 Financial performance
10.6.1.3 Product benchmarking
10.6.1.4 Strategic initiatives
10.6.2 Cibus
10.6.2.1 Company overview
10.6.2.1.1 Nucelis
10.6.2.2 Financial performance
10.6.2.3 Product benchmarking
10.6.2.4 Strategic initiatives
10.6.3 Recombinetics, Inc
10.6.3.1 Company overview
10.6.3.2 Financial performance
10.6.3.3 Product benchmarking
10.6.3.4 Strategic initiatives
10.6.4 Sangamo
10.6.4.1 Company overview
10.6.4.2 Financial performance
10.6.4.3 Product benchmarking
10.6.4.4 Strategic initiatives
10.6.5 Editas Medicine
10.6.5.1 Company overview
10.6.5.2 Financial performance
10.6.5.3 Product benchmarking
10.6.5.4 Strategic initiatives
10.6.6 Precision Biosciences
10.6.6.1 Company overview
10.6.6.2 Financial performance
10.6.6.3 Product benchmarking
10.6.6.4 Strategic initiatives
10.6.7 CRISPR THERAPEUTICS
10.6.7.1 Company overview
10.6.7.2 Financial performance
10.6.7.3 Product benchmarking
10.6.7.4 Strategic initiatives
10.6.8 Intellia Therapeutics, Inc.
10.6.8.1 Company overview
10.6.8.2 Financial performance
10.6.8.3 Product benchmarking
10.6.8.4 Strategic initiatives
10.6.9 Caribou Biosciences, Inc
10.6.9.1 Company overview
10.6.9.2 Financial performance
10.6.9.3 Product benchmarking
10.6.9.4 Strategic initiatives
10.6.10 Cellectis
10.6.10.1 Company overview
10.6.10.2 Financial performance
10.6.10.3 Product benchmarking
10.6.10.4 Strategic initiatives
10.6.11 AstraZeneca
10.6.11.1 Company overview
10.6.11.2 Financial performance
10.6.11.3 Product benchmarking
10.6.11.4 Strategic initiatives
10.6.12 Takara Bio Inc.
10.6.12.1 Company overview
10.6.12.2 Financial performance
10.6.12.3 Product benchmarking
10.6.12.4 Strategic initiatives
10.6.13 Horizon Discovery Group plc
10.6.13.1 Company overview
10.6.13.2 Financial performance
10.6.13.3 Product benchmarking
10.6.13.4 Strategic initiatives
10.6.14 Integrated DNA Technologies, Inc.
10.6.14.1 Company overview
10.6.14.2 Financial performance
10.6.14.3 Product benchmarking
10.6.15 Transposagen Biopharmaceuticals, Inc.
10.6.15.1 Company overview
10.6.15.2 Financial performance
10.6.15.3 Product benchmarking
10.6.16 GenScript
10.6.16.1 Company overview
10.6.16.2 Financial performance
10.6.16.3 Product benchmarking
10.6.16.4 Strategic initiatives
10.6.17 New England Biolabs
10.6.17.1 Company overview
10.6.17.2 Financial performance
10.6.17.3 Product benchmarking
10.6.17.4 Strategic initiatives
10.6.18 OriGene Technologies, Inc.
10.6.18.1 Company overview
10.6.18.2 Financial performance
10.6.18.3 Product benchmarking
10.6.18.4 Strategic initiatives
10.6.19 bluebird bio, Inc.
10.6.19.1 Company overview
10.6.19.2 Financial performance
10.6.19.3 Product benchmarking
10.6.19.4 Strategic initiatives
10.6.20 Lonza
10.6.20.1 Company overview
10.6.20.2 Financial performance
10.6.20.3 Product benchmarking
10.6.20.4 Strategic initiatives
10.6.21 Thermo Fisher Scientific, Inc.
10.6.21.1 Company overview
10.6.21.2 Financial performance
10.6.21.3 Product benchmarking
10.6.21.4 Strategic initiatives